Login to Your Account

Dynavax shares leap on phase III Heplisav-B data; BLA later this year

By Michael Fitzhugh
Staff Writer

Thursday, January 7, 2016

Dynavax Technologies Corp. investors rejoiced Thursday as positive top-line results from a phase III trial comparing the safety and immunogenicity of its investigational hepatitis B vaccine, Heplisav-B, to Glaxosmithkline plc's Engerix-B emboldened the company to resubmit its BLA by the end of March.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription